Innoscripta H1 2026 slides: 43% growth amid migration headwinds

Innoscripta reported H1 2026 operating performance of €63.2M (+43% YoY) and adjusted EBIT of €36.4M (+49% YoY), with margin expanding to 57.7% (+220 bps). Shares fell nearly 9% to $75 as a Clusterix software platform migration temporarily disrupted submissions and delayed some revenue recognition into 2H 2026, though management framed it as a timing shift (not lost business). The company reaffirmed full-year guidance of €140M revenue and €80M EBIT, supported by strong cash generation (H1 unlevered FCF €24.9M; adjusted FCF €39.8M).

Analysis

The selloff reads more like a confidence shock around systems execution than a reset of unit economics. In workflow-heavy compliance software, the market usually punishes any sign that revenue recognition can slip by a quarter because throughput, not logo count, is the real operating lever; if the migration caused submissions to sit in a queue, the key question is whether those cases are truly deferred or whether some portion will leak to slower competitors and consultants.

Second-order beneficiaries are the larger, trust-heavy compliance platforms and professional-services-adjacent vendors that can market auditability and process reliability. That argues for relative strength in names like Wolters Kluwer, Thomson Reuters, and RELX if regulatory scrutiny keeps tightening, while smaller local tax-tech entrants in France/UK/US may see longer sales cycles and more pricing pressure as buyers demand implementation proof before switching. The company’s international push also implies a 2026 expense ramp before revenue contributes, so the next 1-3 months are more about evidence of catch-up than about the long-term TAM story.

Contrarian view: the market may be overestimating how permanent a migration-induced slowdown is, but underestimating how often these issues expose hidden operational fragility. If Q3 submission volumes and cash conversion rebound cleanly, the drawdown should recover; if they do not, this becomes a credibility problem and the multiple can compress another leg. Time horizon matters: near term this is a trading event, over 6-18 months it is a test of whether the platform can scale without recurring execution taxes.

Key Decisions for Investors

• Do not chase the 9% selloff immediately; wait 2-6 weeks for evidence that submission volumes and revenue recognition are normalizing before considering a long entry.
• If you want to express the regulatory-documentation tailwind, prefer long Wolters Kluwer (WKL.AS), Thomson Reuters (TRI), or RELX (RELX.L) as higher-confidence beneficiaries of tighter auditability requirements.
• Set a downside alert on any subsequent guidance reset or if sequential revenue/submission recovery fails to show up in the next quarter; that would invalidate the 'timing only' thesis and likely justify another 15-25% derating.
• For a relative-value expression, pair long quality compliance platforms (WKL.AS / RELX.L) against a basket of smaller, execution-sensitive software names with comparable workflow dependence; the migration risk should favor incumbents with lower implementation volatility.
• Watch cash conversion and churn more than headline growth: if collections stay above invoiced revenue and churn remains sub-2%, the pullback is likely an opportunity; if either deteriorates, stay out.